Home >> Cosmetics & Personal Care >> Life Sciences >> Life Sciences >>

Global Female Contraceptives Market 2015-2019

Published: Sep-2015 | Format: PDF | Technavio | Number of pages: 73 | Code: MRS - 35077


Contraception, popularly known as birth control or fertility control, is used to prevent pregnancy. There are various temporary and permanent contraceptive methods and devices available in the market. Sterilization is a permanent method that almost eliminates the chances of pregnancy. Temporary methods can either be hormonal or non-hormonal. Hormonal methods include oral contraceptive pills, contraceptive transdermal patches, vaginal rings, hormonal IUDs, and vaginal implants. These methods use synthetic sex hormones - estrogen, progestin, or a combination of both - to prevent ovulation and thicken the cervical mucus. Non-hormonal methods include condoms, cervical caps, diaphragms, non-hormonal IUDs, sponges, and withdrawal methods.

The analysts forecast global female contraceptive market to grow at a CAGR of 3.0% over the period 2014-2019.

Covered in this report

This report covers the present scenario and the growth prospects of the global female contraceptive market for the period 2015-2019. This report considers 2014 as the base year and provides data for the trailing 12 months.

This report covers the following types of female contraceptive:

  • Devices (IUDs, Sterilization, Subdermal contraceptive implants, Vaginal rings, Female condoms, Non-surgical permanent contraception, Contraceptive diaphragms, and Contraceptive sponges)
  • Drugs (Birth control pills and Emergency pills)

The report, Global Female Contraceptive Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Americas, APAC, and EMEA; it also covers the landscape of the global female contraceptive market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • Allergan
  • Merck
  • Pfizer
  • Teva Pharmaceutical

Other prominent vendors

  • Ansell
  • Church & Dwight
  • Bayer
  • Agile Therapeutics
  • Caya
  • Fuji Latex
  • Janssen Pharmaceuticals
  • HLL Lifecare
  • Lipocine
  • Mayer Laboratories
  • Okamoto Industries
  • Reckitt Benckiser Group
  • Today Sponge
  • Female Health

Key market driver

  • Improved family planning
  • For a full, detailed list, view our report

Key market challenge

  • Lack of social acceptance
  • For a full, detailed list, view our report

Key market trend

  • Increased unplanned pregnancy
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors


Table of Contents

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Market landscape
Five forces analysis

PART 06: Market segmentation by application
Global female contraceptives market by type
Global female contraceptive devices market
Global IUDs market
Global sterilization market
Global subdermal contraceptive implants market
Global vaginal rings market
Global female condoms market
Global non-surgical permanent contraceptive devices market
Global contraceptive diaphragms market
Global contraceptive sponges market
Global female contraceptive drugs market
Global birth control pills market
Global emergency pills market

PART 07: Market segmentation by region
Female contraceptives market in Americas
Female contraceptives market in EMEA
Female contraceptives market in APAC

PART 08: Market drivers

PART 09: Impact of drivers

PART 10: Market challenges

PART 11: Impact of drivers and challenges

PART 12: Market trends

PART 13: Vendor landscape
Vendor investment opportunity

PART 14: Analysis of other key vendors

PART 15: Key vendor analysis
Allergan
Merck
Pfizer
Teva Pharmaceuticals

PART 16: Appendix
List of abbreviations

List of Exhibits

Exhibit 01: Product offerings
Exhibit 02: Global female contraceptives market 2014-2019 ($ millions)
Exhibit 03: Five forces analysis
Exhibit 04: Global female contraceptives market by type 2014 and 2019
Exhibit 05: Global female contraceptives market by type 2014-2019 ($ millions)
Exhibit 06: Global female contraceptives market by type 2014-2019
Exhibit 07: Global female contraceptives market by devices 2014-2019 ($ millions)
Exhibit 08: Global female contraceptive devices market by type 2014 and 2019
Exhibit 09: Global IUD's market 2014-2019 ($ millions)
Exhibit 10: Global sterilization market 2014-2019 ($ millions)
Exhibit 11: Global subdermal contraceptive implants market 2014-2019 ($ millions)
Exhibit 12: Global vaginal rings market 2014-2019 ($ millions)
Exhibit 13: Global female condoms market 2014-2019 ($ millions)
Exhibit 14: Global non-surgical permanent contraceptive devices market 2014-2019 ($ millions)
Exhibit 15: Global contraceptive diaphragms market 2014-2019 ($ millions)
Exhibit 16: Global contraceptive sponges market2014-2019 ($ millions)
Exhibit 17: Global contraceptive drugs by product type
Exhibit 18: Global female contraceptive drugs market 2014-2019 ($ millions)
Exhibit 19: Global female contraceptives drugs market by type
Exhibit 20: Global birth control pills market 2014-2019 ($ millions)
Exhibit 21: Global emergency pills market 2014-2019 ($ millions)
Exhibit 22: Global female contraceptives by region 2014-2019
Exhibit 23: Female contraceptive market in Americas 2014-2019 ($ millions)
Exhibit 24: Female contraceptives market in EMEA 2014-2019 ($ millions)
Exhibit 25: Female contraceptive market in APAC 2014-2019 ($ millions)
Exhibit 26: Effectiveness of female contraception by type
Exhibit 27: Impact of drivers
Exhibit 28: Impact of drivers and challenges
Exhibit 29: Unplanned pregnancies by region 2014-2019 ($ millions)
Exhibit 30: Population of women using birth pill for non-contraceptive reasons (%)
Exhibit 31: Vendor investment opportunity
Exhibit 32: Allergen: Business segmentation 2014
Exhibit 33: Allergan: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 34: Pfizer: Business segmentation 2014
Exhibit 35: Pfizer: Geographical segmentation 2014
Exhibit 36: Teva Pharmaceuticals: Business segmentation 2014
Exhibit 37: Teva Pharmaceuticals: Business segmentation by revenue 2013 and 2014 ($ millions)

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode
Single User | $(USD)2500 View Pricing